Cargando…

P03-024 – Early onset IBD treated by tocilizumab

Detalles Bibliográficos
Autores principales: Helbling, R, Nyddeger, A, Angelini, F, Von Scheven Gete, A, Hofer, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952214/
http://dx.doi.org/10.1186/1546-0096-11-S1-A222
_version_ 1782307185597874176
author Helbling, R
Nyddeger, A
Angelini, F
Von Scheven Gete, A
Hofer, M
author_facet Helbling, R
Nyddeger, A
Angelini, F
Von Scheven Gete, A
Hofer, M
author_sort Helbling, R
collection PubMed
description
format Online
Article
Text
id pubmed-3952214
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39522142014-03-24 P03-024 – Early onset IBD treated by tocilizumab Helbling, R Nyddeger, A Angelini, F Von Scheven Gete, A Hofer, M Pediatr Rheumatol Online J Meeting Abstract BioMed Central 2013-11-08 /pmc/articles/PMC3952214/ http://dx.doi.org/10.1186/1546-0096-11-S1-A222 Text en Copyright © 2013 Helbling et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Abstract
Helbling, R
Nyddeger, A
Angelini, F
Von Scheven Gete, A
Hofer, M
P03-024 – Early onset IBD treated by tocilizumab
title P03-024 – Early onset IBD treated by tocilizumab
title_full P03-024 – Early onset IBD treated by tocilizumab
title_fullStr P03-024 – Early onset IBD treated by tocilizumab
title_full_unstemmed P03-024 – Early onset IBD treated by tocilizumab
title_short P03-024 – Early onset IBD treated by tocilizumab
title_sort p03-024 – early onset ibd treated by tocilizumab
topic Meeting Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952214/
http://dx.doi.org/10.1186/1546-0096-11-S1-A222
work_keys_str_mv AT helblingr p03024earlyonsetibdtreatedbytocilizumab
AT nyddegera p03024earlyonsetibdtreatedbytocilizumab
AT angelinif p03024earlyonsetibdtreatedbytocilizumab
AT vonschevengetea p03024earlyonsetibdtreatedbytocilizumab
AT hoferm p03024earlyonsetibdtreatedbytocilizumab